SCHEMBL3244848

SCHEMBL3244848

[CH2]c1ccccc1Cc1ccccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.50
TAAR1 Q96RJ0 1/20 0.50
CHRM2 P08172 2/20 0.48
CHRM1 P11229 1/20 0.48
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
IDH1 O75874 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA12 O43570 1/20 0.46
CA4 P22748 1/20 0.46
CA14 Q9ULX7 1/20 0.46
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CNR2 P34972 2/20 0.46
SIGMAR1 Q99720 1/20 0.44
AOC3 Q16853 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296809 0.87 IDO1 (0.61) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL2223002 0.80 HSPA5 (0.46) IDO1TAAR1MAPT
SCHEMBL22800045 0.78 IDO1 (0.52) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL8035410 0.78 CNR2 (0.55) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL9235134 0.77 ABCB1 (0.50) IDO1CA1CA2CA7CA9
SCHEMBL24631774 0.76 IDO1 (0.55) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL10987745 0.76 HSPA5 (0.64) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL5158259 0.76 IDO1 (0.50) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL10388544 0.76 ALDH1A1 (0.59) IDO1TAAR1CHRM2CHRM1ALDH1A1
SCHEMBL8611014 0.76 IDO1 (0.50) IDO1TAAR1CHRM2CHRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 IDO1 527/4885TAAR1 436/4885CHRM2 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.